Kiniksa Pharmaceuticals, Ltd.
KNSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $423,239 | $270,259 | $220,180 | $38,544 |
| % Growth | 56.6% | 22.7% | 471.2% | – |
| Cost of Goods Sold | $60,910 | $56,524 | $22,895 | $9,100 |
| Gross Profit | $362,329 | $213,735 | $197,285 | $29,444 |
| % Margin | 85.6% | 79.1% | 89.6% | 76.4% |
| R&D Expenses | $111,623 | $76,097 | $65,490 | $99,297 |
| G&A Expenses | $156,578 | $0 | $0 | $0 |
| SG&A Expenses | $168,011 | $129,427 | $97,951 | $85,948 |
| Sales & Mktg Exp. | $11,433 | $0 | $0 | $0 |
| Other Operating Expenses | $128,311 | $33,407 | $24,071 | $835 |
| Operating Expenses | $407,945 | $238,931 | $187,512 | $186,080 |
| Operating Income | -$45,616 | -$25,196 | $9,773 | -$156,636 |
| % Margin | -10.8% | -9.3% | 4.4% | -406.4% |
| Other Income/Exp. Net | $9,464 | $8,544 | $1,253 | $97 |
| Pre-Tax Income | -$36,152 | -$16,652 | $11,026 | -$156,539 |
| Tax Expense | $7,041 | -$30,736 | -$172,337 | $1,385 |
| Net Income | -$43,193 | $14,084 | $183,363 | -$157,924 |
| % Margin | -10.2% | 5.2% | 83.3% | -409.7% |
| EPS | -0.6 | 0.2 | 2.64 | -2.3 |
| % Growth | -400% | -92.4% | 214.8% | – |
| EPS Diluted | -0.6 | 0.2 | 2.6 | -2.3 |
| Weighted Avg Shares Out | 71,424 | 70,059 | 69,382 | 68,577 |
| Weighted Avg Shares Out Dil | 71,424 | 71,923 | 70,421 | 68,577 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9,464 | $8,544 | $1,253 | $97 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,695 | $2,341 | $2,402 | $2,355 |
| EBITDA | -$43,921 | -$22,855 | $12,175 | -$154,281 |
| % Margin | -10.4% | -8.5% | 5.5% | -400.3% |